About PolyNovo Limited (PNV)
PolyNovo Limited is a Medical Devices company operating in the Healthcare sector. The company is headquartered in Port Melbourne, Australia. PNV has been publicly traded since 1998, giving it 28+ years of trading history.
PolyNovo Limited (PNV) has been publicly traded since 1998, making it a 28-year-old public company. It operates in the Medical Devices industry within the Healthcare sector. The company is headquartered in Port Melbourne, Australia and employs approximately 301 people. With a market capitalization of A$649 million, PNV is a smaller company with higher growth potential.
PNV trades on the Australian Securities Exchange and is classified as a small-cap-cap stock with a market capitalization of approximately A$649 million. The company employs approximately 301 people worldwide.
Key Statistics
- Current Price
- A$0.94
- Market Cap
- A$649.39M
- 52-Week High
- A$1.72
- 52-Week Low
- A$0.87
- Sector
- Healthcare
- Industry
- Medical Devices
PNV Investment Performance
PNV has declined 23.6% year-to-date in 2026. Over the past 5 years, a A$1,000 investment in PNV would have grown to A$347, representing a -65.3% total return. Since its IPO in 1998, a A$1,000 investment would now be worth A$113.
A$1,000 Invested in PolyNovo Limited (PNV)
How much would A$1,000 invested in PNV be worth today?
What would A$1,000 invested in PNV 1 year ago be worth today?
A A$1,000 investment in PolyNovo Limited (PNV) in 2025 would be worth A$821 as of March 2026, representing a -17.9% total return.
What would A$1,000 invested in PNV 3 years ago be worth today?
A A$1,000 investment in PolyNovo Limited (PNV) in 2023 would be worth A$525 as of March 2026, representing a -47.5% total return.
What would A$1,000 invested in PNV 5 years ago be worth today?
A A$1,000 investment in PolyNovo Limited (PNV) in 2021 would be worth A$347 as of March 2026, representing a -65.3% total return.
What would A$1,000 invested in PNV 10 years ago be worth today?
A A$1,000 investment in PolyNovo Limited (PNV) in 2016 would be worth A$3,357 as of March 2026, representing a +235.7% total return.
What would A$1,000 invested in PNV at IPO be worth today?
A A$1,000 investment in PolyNovo Limited (PNV) at IPO would be worth A$113 as of March 2026, representing a -88.7% total return.
Monthly Returns Heatmap
Over the past 27+ years (328 months), PolyNovo Limited (PNV) has averaged a monthly return of +1.65% with a median return of +0.00%. The stock had 153 positive months (47%) and 154 negative months (47%). The best month in PNV's history was December 2015 with a +81.3% return, while the worst was May 2004 at -85.0%. Historically, October tends to be the strongest month (averaging +7.8%), and March the weakest (-3.1%).
PNV's longest winning streak was 7 consecutive months of gains, while its longest losing streak was 6 consecutive months of losses. The best full year was 1999 with a cumulative return of +153.7%, and the worst was 2007 at -178.0%.
Annual Returns
Over 28 years of trading history, PolyNovo Limited (PNV) has delivered an average annual return of +28.72% with a median return of +14.80%. The compound annual growth rate (CAGR) is -7.50%. The stock posted gains in 16 years (57%) and losses in 12 years (43%).
PNV's best year was 1999 with a +252.94% gain, while the worst was 2007 at -95.03%. The longest streak of consecutive positive years was 8, and the longest losing streak was 2 years. PNV achieved double-digit gains (10%+) in 15 years. It suffered double-digit losses in 11 years.
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -23.58% | A$1.23 | A$0.94 |
| 2025 | -39.71% | A$2.04 | A$1.23 |
| 2024 | +23.26% | A$1.65 | A$2.04 |
| 2023 | -18.07% | A$2.02 | A$1.65 |
| 2022 | +32.46% | A$1.52 | A$2.02 |
| 2021 | -60.70% | A$3.88 | A$1.52 |
| 2020 | +96.95% | A$1.97 | A$3.88 |
| 2019 | +231.09% | A$0.60 | A$1.97 |
| 2018 | +14.42% | A$0.52 | A$0.60 |
| 2017 | +79.31% | A$0.29 | A$0.52 |
| 2016 | +0.00% | A$0.29 | A$0.29 |
| 2015 | +218.68% | A$0.09 | A$0.29 |
| 2014 | +15.19% | A$0.08 | A$0.09 |
| 2013 | +79.55% | A$0.04 | A$0.08 |
| 2012 | -21.43% | A$0.06 | A$0.04 |
| 2011 | +115.38% | A$0.03 | A$0.06 |
| 2010 | -13.33% | A$0.03 | A$0.03 |
| 2009 | +15.38% | A$0.03 | A$0.03 |
| 2008 | -36.59% | A$0.04 | A$0.03 |
| 2007 | -95.03% | A$0.82 | A$0.04 |
| 2006 | +79.35% | A$0.46 | A$0.82 |
| 2005 | -64.06% | A$1.28 | A$0.46 |
| 2004 | -83.22% | A$7.63 | A$1.28 |
| 2003 | +62.69% | A$4.69 | A$7.63 |
| 2002 | -5.63% | A$4.97 | A$4.69 |
| 2001 | +36.54% | A$3.64 | A$4.97 |
| 2000 | -87.62% | A$29.40 | A$3.64 |
| 1999 | +252.94% | A$8.33 | A$29.40 |
PNV Investment Analysis: Valuation, Risk & Dividends
Key factors to consider when evaluating PolyNovo Limited as an investment
Valuation
PNV currently trades at a trailing P/E ratio of 94.0, which is considered high relative to the broader market. The forward P/E of 30.1 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 7.8. The price-to-sales ratio is 4.7.
Dividends
PolyNovo Limited does not currently pay a dividend, choosing to reinvest earnings back into the business for growth.
Risk & Volatility
PNV has a beta of 1.43, indicating it is significantly more volatile than the overall market. The stock's 52-week range is A$0.86 to A$1.72, and it currently trades near its 52-week low.
Analyst Ratings
Based on 8 analyst opinions, PNV has a consensus "strong_buy" rating. The average price target of A$1.74 suggests 85.0% upside from current levels.
Frequently Asked Questions: PNV
What sector is PNV in? ▼
PNV operates in the Healthcare sector, specifically in the Medical Devices industry. This sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers.
How has PNV performed historically? ▼
Over 28 years of trading history, PNV has posted gains in 16 years (57% of the time). The best year was 1999 with a +252.9% return. Past performance does not guarantee future results.
How can I invest in PNV? ▼
You can invest in PNV through any brokerage account that offers access to the Australian Securities Exchange. Popular options include commission-free brokers like Fidelity, Charles Schwab, or Robinhood (US), or international brokers like Interactive Brokers. You can buy individual shares or invest through ETFs that hold PNV.
Does PNV pay dividends? ▼
PolyNovo Limited does not currently pay a dividend, choosing to reinvest earnings back into the business for growth.
What does PolyNovo Limited do? ▼
PolyNovo Limited is a Medical Devices company operating in the Healthcare sector. The company is headquartered in Port Melbourne, Australia.
What sector is PNV in? ▼
PNV operates in the Healthcare sector, specifically in the Medical Devices industry.
When did PNV go public? ▼
PolyNovo Limited went public in 1998, making it a 28-year-old public company as of 2026.
How much would A$1,000 invested in PNV 5 years ago be worth today? ▼
A A$1,000 investment in PNV five years ago would be worth approximately A$347 today, representing a -65.3% return.
How much would A$1,000 invested in PNV 10 years ago be worth today? ▼
A A$1,000 investment in PNV ten years ago would be worth approximately A$3,357 today, representing a 235.7% total return over the decade.
What is PNV's 3-year return? ▼
Over the past 3 years, PNV has returned -47.5%. A A$1,000 investment would have grown to A$525.
How much would A$1,000 invested in PNV at IPO be worth today? ▼
If you invested A$1,000 in PNV at its IPO in 1998, it would be worth approximately A$113 today, a -88.7% return over 28 years.
Does PNV pay dividends? ▼
No, PolyNovo Limited does not currently pay a dividend. The company reinvests its earnings into growth.
What is PNV's market cap? ▼
PolyNovo Limited has a market capitalization of A$649 million, classifying it as a small-cap company.
What is PNV's P/E ratio? ▼
PNV has a trailing P/E ratio of 94.0 and a forward P/E of 30.1, which measures how much investors are paying per dollar of earnings.
Is PNV a buy, hold, or sell? ▼
Based on 8 opinions, PNV has a consensus "strong_buy" rating. The average price target is A$1.74.
Last updated: 3/15/2026